(adds more information)Trading in Pharma Lundensis' share was halted on 3 July 2026 after a decision by Spotlight Stock Market. The trading halt applies until further notice. According to the marketplace, the reason is uncertainty regarding the company's position and that continued trading is deemed likely to harm investors' interests. The Swedish Financial Supervisory Authority has been informed and has decided that the trading halt shall remain in place until further notice.It is already known that the share is to be delisted from Spotlight. In a press release during the morning of 3 July, Pharmalundensis wrote that the delisting takes place on Wednesday 8 July and it had previously been announced that the last trading day would be 14 July. It is worth noting that in the upbeat press release the company described it as "the last chance to join Pharmalundensis' journey"."I assess that the first of our planned clinical studies may be completed in 12-18 months. If our studies are successful, which I feel completely sure they will be, the value of Pharmalundensis' share will increase astronomically, perhaps by 1000 times or more. Then I expect bids will rain down on Pharmalundensis from large companies that want to buy into our treatment," the company writes. About 50 minutes after the company's press release, the trading halt was announced.